StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Frequently asked questions
What sector does StageZero Life Sciences Ltd (SZLS) operate in?
StageZero Life Sciences Ltd belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is StageZero Life Sciences Ltd (SZLS) current stock price?
As of the latest data, StageZero Life Sciences Ltd stock price is CA$0.04, with a previous close of CA$0.04.
What is StageZero Life Sciences Ltd (SZLS) current market capitalization?
StageZero Life Sciences Ltd market cap is approximately 4.94 million.
What is StageZero Life Sciences Ltd (SZLS) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.16.
Does StageZero Life Sciences Ltd (SZLS) pay dividends?
No. StageZero Life Sciences Ltd does not pay a dividend.
What is StageZero Life Sciences Ltd (SZLS) beta (volatility) score?
StageZero Life Sciences Ltd has a beta of 0.074, indicating lower volatility than the overall market.